Israel has good news after administering the Pfizer Wuhan pneumonia (novel coronavirus disease, COVID-19) vaccine to the public, with the protection rate exceeding Pfizer’s previously announced 95 percent, reaching a staggering 99.985 percent.
According to the Times of Israel, Maccabi Healthcare Services noted that 128,000 people received the second dose of the vaccine and only 20 had contracted the disease after one week, a rate as low as 0.015 percent.
Immunologist Cyrille Cohen revealed that about 0.65% of the total Israeli population was diagnosed during that week, so although Maccabi’s data lacked a control sample, it does exceed the 95% effectiveness of the Pfizer clinical trial if the entire country is considered an imperfect control group.
This exciting result confirms the high protection rate of Pfizer’s vaccine, Cohen said. Maccabi analyst Anat Ekka Zohar also said that although this is very early data, it is also quite important information because the world is looking to Israel to see how effective the vaccine is.
Recent Comments